Group items tagged

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

The Summer Undergraduate Research Fellowship (SURF) Program at Cincinnati Children's Hospital Medical Center offers undergraduates the chance to explore clinical and basic science research in laboratories in the Department of Pediatrics, University of Cincinnati College of Medicine. The primary goal is to provide students with a foundation for making career choices in the biomedical sciences. Students have the opportunity to work with one of more than 700 faculty members at Cincinnati Children's Hospital Medical Center, many of whom have active research programs that cover all areas of pediatric medicine, including the study of developmental biology, congenital disorders, genetic diseases, cancer, cardiology, neurology and immunology.

Conducting exceptional clinical research requires close collaboration between academic and industry professionals. Our year-long Clinical Research Fellowships in Oncology, Neurology, Immunology, Ophthalmology, Pulmonary Medicine and other specialty areas give fellows the crucial experience they need to transform knowledge into practice, working directly with top institutions and physicians to strengthen our commitment to developing innovative new medicines.

The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. The Teal Innovator Award will provide the Principal Investigator (PI) with the funding and freedom to pursue his/her most novel, visionary, high-risk ideas that could significantly impact the field of ovarian cancer research or patient care. The proposed Teal Innovator must be highly recognized in his/her field and present evidence of this recognition. Examples include, but are not limited to, recognition at the level of endowed chair; membership in the National Academy of Sciences, National Academy of Engineering, or Institute of Medicine; Chairmanship of the American Association for Cancer Research; or other national or international recognition.

The AAAS Early Career Award for Public Engagement with Science, established in 2010, recognizes early-career scientists and engineers who demonstrate excellence in their contribution to public engagement with science activities. A monetary prize of $5,000, a commemorative plaque, complimentary registration to the AAAS Annual Meeting, and reimbursement for reasonable hotel and travel expenses to attend the AAAS Annual Meeting to receive the prize are given to the recipient. Nominee must be an early-career scientist or engineer in academia, government or industry actively conducting research in any scientific discipline (including social sciences and medicine).  "Early career" is defined as an individual who has been in his/her current field for less than seven years and pre-tenure or job equivalent. Post-doctoral students are eligible for this award. Nominee will have demonstrated excellence in his/her contribution to public engagement with science activities, with a focus on interactive dialogue between the individual and a non-scientific, public audience(s). Types of public engagement activities might include: informal science education, public outreach, public policy, and/or science communication activities, such as mass media, public dialogue, radio, TV and film, science café, science exhibit, science fair, and social and online media.

The program is designed to bring together diverse interdisciplinary groups with expertise in genetics/genomics, immunology, microbiology, and proteomics along with the more traditional areas of parturition research such as maternal fetal medicine, obstetrics, and pediatrics to address scientific issues related to preterm birth. The fund has committed $3 million for the initiative and anticipates awarding five grants of up to $600,000 over a four-year period ($150,000 per year).

Cell-based therapies, especially immune cells, have the potential to revolutionize human healthcare in various different contexts, including cancer and personalized medicine. For example, CAR (Chimeric antigen receptor) T-cell therapy for cancer requires modification, in vitro culture and expansion of human T-cells.   Manufacturing of therapeutic cells as the end product presents major engineering challenges.  New therapies and cell-based products depend critically on the development of robust, reliable and reproducible biomanufacturing technologies.

The American Society for Radiation Oncology is accepting applications for its 2019 Minority Summer Fellowship Award. The annual program is designed to introduce medical students from backgrounds that are underrepresented in medicine to the discipline of radiation oncology early in their medical education. Although medical students in all years are encouraged to apply, preference will be given to first- and second-year students. In an effort to promote radiation oncology as a career choice, the fellowship will expose medical students to clinical, basic, and translational research questions in radiation oncology. The fellowship provides each student with a $4,500 package that includes a $3,500 stipend for the eight-week training program (exceptions can be made for a longer program but will need to be approved by ASTRO's Committee on Health Equity, Diversity and Inclusion, or "CHEDI") and $1,000 toward the cost of travel to the organization's 2019 annual meeting. To be eligible, applicants must be enrolled in a United States medical school and be able to identify a mentor with a successful record of research productivity. The mentor should be an ASTRO member. In addition, research must be undertaken at a North American institution during the summer of 2019.

The foundation seeks research proposals dedicated to the following priority areas: immunotherapy for the treatment of metastatic, lethal prostate cancer; targeted radionuclide therapy for advanced prostate cancer; new systemic precision treatments for metastatic, lethal prostate cancer (including those targeting the currently "undruggable"); first-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer; mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents; correlative research around either clinical trials of novel agents or strategies or standard of care; the development or validation of biomarkers that can guide therapy in patients or further understanding of the mechanisms by which therapies work; tumor microenvironment signaling related to cancer progression (including the immune component); and new data science technologies for analysis of genomic information to advance precision medicine.

The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

ENTELLIGENCE, in partnership with Actelion Pharmaceuticals US, supports basic science, translational, and clinical research in the field of cardiopulmonary medicine. The program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research in pulmonary hypertension. To that end, ENTELLIGENCE is accepting applications for its thirteenth annual Young Investigator grant program. Established in 2005, the program provides opportunities for promising young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, clinical, or translational) in the area of pulmonary hypertension specifically related to expanding knowledge of pulmonary vascular pathobiology pathways. In 2018, the program will award a one-year grant of up to $100,000 to fund a mentored project.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

The St. Baldrick's Foundation works hard to be sure that every dollar makes the biggest impact possible in childhood cancer research. The Foundation has held several Research Priorities Summits with many of the country's leading pediatric oncology researchers participating to advise the staff and board of directors on funding priorities. The St. Baldrick's team and Scientific Advisors meet regularly to be sure St. Baldrick's funds make the greatest impact on pediatric cancer research. Current funding priorities are divided into four categories: * New discovery research * Translational research and early phase clinical trials * Phase III clinical trials & infrastructure support of participating institutions (primarily the fall grant cycle) * Education of new pediatric oncology researchers In addition to research to understand the biology of childhood cancers and discover leads to more effective treatments, topics of interest include, but are not limited to: * Adolescents & young adults * Survivorship, outcomes, and quality of life * Supportive care * Epidemiology and pediatric cancer predispositions * Precision medicine * Alternative & complementary therapies

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigation

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality. In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions.